SCIENTURE HOLDINGS Reaffirms Plan To Commercially Roll Out REZENOPY In Q2

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial update on ARBLI™ (losartan potassium) oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook—including reaffirming its plan to commercially launch REZENOPY™, a life-saving opioid overdose emergency treatment, in the second quarter of 2026.

Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to ARBLI™ across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions (IQVIA MAT Dec 2025) U.S. losartan market.